Senzer launches Critical Care Division for anti-viral COVID-19 treatments

Image of magnifying glass and coronavirus to show Senzer launches Critical Care Division for anti-viral COVID-19 treatments

Senzer Pharmaceuticals, a UK company involved in the development, manufacture and licencing of pioneering respiratory products for pharmaceutical formulations, has launched a Critical Care Division, which will utilise its expertise in respiratory pharmaceuticals to create targeted anti-viral treatments for COVID-19.

The Critical Care Division is working on formulating two specific medicines, with anti-viral properties, to allow them to be inhaled directly into the respiratory tract. Senzer is also in advanced discussions with a leading London teaching hospital to undertake a randomised placebo-controlled trial, to explore how the two formulations may reduce the number of COVID-19 patients requiring intensive care treatment.

The targeted delivery of anti-virals to where the viral load from COVID-19 is heaviest, the respiratory tract, is at the centre of Senzer’s Critical Care strategy. The Company is using pressurised metered dose inhalers (pMDI), as these are already well known to healthcare professionals. Senzer said its supply chain will be able to deliver about 30m doses annually, and these can be sent through its international distributor to any country that may wish to access the investigational therapies for further clinical research.

The Company’s strategy is based on re-formulating approved pharmaceutical medicines, with known safety profiles for other medical conditions. Besides the first two candidate therapies, Senzer’s Critical Care division is also currently studying two other pharmaceutical products, which may also have promise as inhaled frontline treatments for COVID-19.

Commenting, Alex Hearn, CEO of Senzer Pharmaceuticals, said: “When the COVID pandemic struck we quickly realised that our expertise in respiratory pharmaceuticals had specific relevance. We have considerable formulation expertise within the team, as well as an understanding of the regulatory environment, and so are currently 100% focused on deploying all of our requisite skills to ensure we can develop and deliver novel investigational medicines for clinical trial use in the shortest possible time, in order to support the front line medical staff and their patients during this crisis.”

Keep up to date with COVID-19 news and features for pharma and healthcare